BPaL/M is a six-month all-oral regimen recommended by the World Health Organization (WHO) to treat most forms of ...

TB Alliance's third licensed manufacturer makes pretomanid available through the Global Drug Facility, further improving affordability and accessTB Alliance applauds a new milestone in the fight ...

Global access to tuberculosis (TB) medicine pretomanid received a shot in the arm, as its price saw a 25% drop, thanks to a ...

TB Alliance. “This partnership with TaBriX and UoM will strengthen the pipeline for the next generation of therapies that can help bring an end to this deadly pandemic.” Professor Lydia Tabernero, the ...

NEW YORK, Feb. 23, 2023 /PRNewswire/ -- The TB Alliance Board of Directors has elected David Norton as Chairperson of the Board. In this role, David will provide leadership to a diverse Board ...

The Global Alliance for TB Drug Development and Tibotec have joined forces to develop a potential first-in-class drug for both drug-susceptible and drug-resistant tuberculosis. In June ...

M4TB, through its participation in ERA4TB – a European Union’s Horizon 2020 research and innovation program – is supporting initial development of a long-acting injectable ...

By Sharon AtienoThe price of pretomanid, the newest tuberculosis (TB) medicine, dropped to less than a dollar per day in April.The drug is now available through the Global Drug Facility (GDF) for ...

NEW YORK, April 24, 2025 /PRNewswire/ -- TB Alliance applauds a new milestone in the fight against drug-resistant tuberculosis (DR-TB): a 25% price reduction for pretomanid, a key component of the ...

NEW YORK, April 24, 2025 /PRNewswire/ -- TB Alliance applauds a new milestone in the fight against drug-resistant tuberculosis (DR-TB): a 25% price reduction for pretomanid, a key component of the ...